Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Oncopeptides: revenue in second quarter rises 62%, shares jump

Oncopeptides reported net sales of SEK 31.1m in Q2 2026, up 62% year‑on‑year, and SEK 56.5m in the first half (+74%). Gross margin in H1 was 98%, the EBIT loss narrowed to SEK 86.2m, and operating costs fell slightly. The company reported SEK 158m in cash after a March rights issue and reiterated its target to reach positive cash flow in 2027. The share rose about 10% in early trading but remains well below the 52‑week high. » More on de.investing.com
Oncopeptides: Q3 revenue rises 174% – profitability targeted by end of 2026

Oncopeptides reports Q3 2025 revenue of SEK 20.2m, up 174% year‑on‑year, and a gross margin of 99%. EBIT improved to -SEK 47.1m but remained negative, while operating expenses were slightly reduced. After an oversubscribed rights issue, liquidity stands at SEK 147.9m; the company aims for positive cash flow by the end of 2026. Oncopeptides is advancing commercialization in Europe (Germany, Spain, Italy) and is negotiating partnerships in Japan, but uncertainty over growth and timing failed to reassure investors, sending the stock down nearly 14%. » More on de.investing.com
Oncopeptides achieves 174% revenue increase, stock falls sharply in pre-market

Oncopeptides reported Q3 2025 net revenue growth of 174% to SEK 20.2m and a gross profit of SEK 19.9m with a gross margin of 99%. Operating expenses fell 3% and EBIT improved from -SEK 61.3m to -SEK 47.1m; after a capital raise liquidity stands at SEK 147.9m. Despite the progress, the stock fell 12.44% in pre-market trading as investors voiced concerns about operational challenges, market expansion and the timeline to profitability by end-2026. Management plans to expand its market presence in Europe and will present further details at the capital markets day on 13 November. » More on de.investing.com
Oncopeptides reports strong Q2 growth, plans SEK 150m rights issue

Oncopeptides posted net sales of SEK 19.2m in Q2 2025 (+45% q/q, +135% y/y) and has recorded three quarters with >30% growth, while the stock fell sharply in pre-market trading. The company plans a rights issue of SEK 150m, holds SEK 70m in cash and is targeting positive cash flow by 2026. Pepaxti was included in EMN guidelines and approved in markets such as Germany, Spain and Italy; partnership negotiations for Japan are ongoing. » More on de.investing.com

Financials

In the last quarter, Oncopeptides had revenue of €2.51m and net profit of -€3.88m

(EUR)	September 2026	YoY
Revenue	2.51m	37.22%
Gross profit	2.47m	36.92%
Net profit	-3.88m	29.60%
EBITDA	-3.17m	24.62%

Fundamentals

Metric	Value
Market capitalization	€68.75m
Number of shares	431.36m
52-week high/low	€0.52 - €0.11
Dividends	No
Beta	-1.41
P/E ratio	-2.81
PEG ratio	-0.04
P/B ratio	-39.32
P/S ratio	7.38

Company profile

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.